Recent Updates
Recently added Catalysts
SEER Positive Sentiment Score: 65/100

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

Key Takeaway: Seer, Inc. has announced it will release its financial results for the third quarter of 2025 on November 6, 2025. The announcement includes details of a conference call that will be webcasted at 1:30 p.m. Pacific Time. Seer highlights its advancements in proteomics, emphasizing the speed and precision of its innovative technologies, which are designed to overcome the limitations of traditional methods. The company positions itself as a leader in delivering deep, unbiased proteomic insights.

Market Sentiment Analysis

POSITIVE FACTORS

  • Seer is a pioneer in deep, unbiased proteomic insights.
  • The company achieved significant speed and precision with their Proteograph Product Suite.
  • Seer sets a new standard in proteomics that overcomes challenges faced by traditional methods.

Full Press Release Details

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.

Frequently Asked Questions

When will Seer report its Q3 2025 financial results?

Seer will report its Q3 2025 financial results on November 6, 2025.

What time is Seer’s conference call scheduled?

The conference call is scheduled for 1:30 p.m. Pacific Time.

How can I access Seer's financial results presentation?

The presentation can be accessed via live webcast on Seer’s Investor section.

What is Seer's main focus in proteomics?

Seer focuses on deep, unbiased proteomic insights with unmatched precision and speed.

Are Seer’s products intended for diagnostic use?

No, Seer’s products are for research use only and not for diagnostics.

Last updated: Oct 16, 2025